Animal Models of Typical Heterotopic Ossification

Department of Neurology, Northwestern University Feinberg Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA.
BioMed Research International (Impact Factor: 2.71). 01/2011; 2011(263):309287. DOI: 10.1155/2011/309287
Source: PubMed


Heterotopic ossification (HO) is the formation of
marrow-containing bone outside of the normal skeleton. Acquired HO
following traumatic events is a common and costly clinical
complication. In contrast, hereditary HO is rarer, progressive,
and life-threatening. Substantial effort has been directed towards
understanding the mechanisms underlying HO and finding efficient
treatments. However, one crucial limiting factor has been the lack
of relevant animal models. This article reviews the major
currently available animal models, summarizes some of the insights
gained from these studies, and discusses the potential future
challenges and directions in HO research.


Available from: Lixin Kan
  • Source
    • "Several similarities and differences in the microstructure , macrostructure , bone composition , bone remodeling , and pathways have been described ( Kan and Kessler 2011 ; Pearce et al . 2007 ; Viateau and Guillemin 2004 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Both spondylosis and diffuse idiopathic skeletal hyperostosis (DISH) are prevalent in humans and are considered distinct entities. Nowadays, the term spondylosis is in the biomedical literature mostly used when concurrently degenerative disc disease is present. In companion animals, many reports on spondylosis, often without intervertebral disc degeneration, are described. The nomenclature and the definitions of both spondylosis and DISH in biomedical and veterinary literature should be more in line to facilitate comparison. Spondylosis and DISH occur in dogs spontaneously and can co-occur in one animal. Specifically, Boxers may serve as translational disease models for the elucidation of the gene(s) involved in the (etio)pathogenesis of spondylosis and DISH or serve as a test population for newly developed treatment options.
    ILAR journal / National Research Council, Institute of Laboratory Animal Resources 06/2014; 55(1):150-63. DOI:10.1093/ilar/ilu012 · 2.39 Impact Factor
  • Source
    • "Once in the nucleus phospho-SMAD 1/5/8 interacts directly with DNA as either a co-activator or repressor of gene expression (Dudley et al., 1995; Arkell and Beddington, 1997; Gould et al., 2002; Yang et al., 2006). BMP7 has been extensively studied for its ability to induce bone formation and kidney regeneration and it has been approved by Health Canada and FDA to treat bone fractures, non-unions and spinal fusion (Gould et al., 2002; Chang et al., 2003; Zhu et al., 2004; Gregory et al., 2005; White et al., 2007; Song et al., 2008; Desmyter et al., 2008; Kan and Kessler, 2011). Current data from several laboratories , including ours, suggest that BMP7 also contributes to cell survival and differentiation; hence it may potentially assist in the protection and regeneration of the brain following injury or stroke (Chou et al., 2006; Tsai et al., 2007; Bani-Yaghoub et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone morphogenetic protein 7 (BMP7), a member of the transforming growth factor β (TGF-β) superfamily, plays important roles in the development of various tissues and organs in mouse and human. In particular, BMP7 is critical for the formation of the nervous system and it is considered to have therapeutic potential in brain injury and stroke. One approach to make BMP7 more suitable for therapeutic purposes is the development of efficient vectors that allow the consistent, reliable and cost-effective production of the BMP7 protein. In this study, we developed an efficient BMP7 delivery system, using a third generation lentiviral vector to produce functional BMP7 protein. The lentiviral transduction of several human cell types, including human embryonic kidney 293 (HEK293) cells, amniotic fluid cells, NTera2 neurons (NT2-N) and primary neuronal cultures resulted in BMP7 expression. The production of BMP7 protein was achieved for at least 4 weeks post-transduction, as determined by enzyme-linked immunosorbent assay (ELISA). SMAD phosphorylation and neuronal differentiation assays verified the bioactivity and functionality of the lentiviral-based BMP7 protein, respectively. In addition, the intracerebroventricular injection of the lentivirus resulted in exogenous BMP7 expression in both neurons and astrocytes in the mouse brain. Taken together, this gene delivery system provides a reliable source of functional BMP7 protein for future in vitro and in vivo studies.
    Journal of Neuroscience Methods 12/2011; 205(1):17-27. DOI:10.1016/j.jneumeth.2011.12.007 · 2.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic heterotopic ossification (HO) is a common clinical condition associated with various orthopedic procedures that involve injury to soft tissues near bone. In this study, we tested the hypothesis that the prophylactic effects of NSAID's in the treatment of HO are mediated via inhibition of the COX-2 enzyme. Here we describe a rat model that simulates HO in the human that was used to test the above hypothesis. Heterotopic ossification was surgically induced in the quadriceps by injury to the muscle and femoral periosteum and transplantation of donor bone marrow cells containing osteoprogenitors into the site of injury. HO was imaged and quantified by micro-CT scanning of femurs removed from sacrificed animals at 6 weeks post-injury, three-dimensional computer reconstructions of the scanned bones and computer-assisted morphometric analysis. Prostaglandin E(2) (PGE(2)) synthesis was quantified using an enzyme immunoassay system. The effects of a nonselective COX inhibitor or specific inhibitors of COX-1 or COX-2 following oral administration on the content of ectopic bone and PGE(2) were also measured. Micro-CT and histological analyses demonstrated that all of the femurs in operated limbs developed HO in the vastus lateralis muscle belly of the quadriceps close to the anterior femur. Only the COX-1,2 nonselective and COX-2 inhibitors significantly decreased HO formation (by about one-third in each case; P < 0.05). PGE(2) synthesis at the site of injury was increased 50- and 100-fold (to 25 ng/g tissue) within 1 and 7 days, respectively, post-injury with the levels declining to near baseline within 2 weeks of surgery. Both the COX-1,2 nonselective and COX-2 inhibitors significantly decreased PGE(2) levels to 25% of control HO levels within 24 h of the first administration, even at low dosages. The COX-1 inhibitor only produced the same effect after 1 week of administration. These findings suggest that although inhibitors of COX-2 or COX-1 reduced PGE(2) synthesis, only the COX-2 enzyme plays a role in the mechanism of traumatic HO.
    Archives of Orthopaedic and Trauma Surgery 03/2008; 128(3):333-44. DOI:10.1007/s00402-007-0436-2 · 1.60 Impact Factor
Show more